Niagen Bioscience, Inc. — Director's Dealing 2025

Nov 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Niagen Bioscience, Inc. (NAGE)
CIK: 0001386570
Period of Report: 2025-11-14

Reporting Person: Pamir Ozan (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-14	Common Stock	P	4464.962	$6.81	Acquired	7372.159	Direct
2025-11-14	Common Stock	P	2220.443	$6.85	Acquired	2220.443	Indirect

Footnotes

F1: The weighted average purchase price for the transaction reported was $6.81, and the range of prices were between $6.7975 and $6.82, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided.